Ashling Wahner

Tacabrutideg's safety profile was tolerable, and the drug had antitumor activity in BTK inhibitor–naive patients with CLL/SLL and other B-cell malignancies.

Treatment with subcutaneous blinatumomab generated high CR rates across 2 dosing regimens in pretreated, relapsed/refractory, Ph-positive B-ALL.

ASCO 2026 highlights show dostarlimab may deliver curative potential in dMMR endometrial cancer, while novel ADCs and fasting reshape ovarian care.

Gilteritinib generated comparable OS outcomes vs midostaurin in newly diagnosed FLT3-mutated AML, failing to meet the phase 3 trial primary end point.

The FDA approved capivasertib plus abiraterone and prednisone for PTEN-deficient metastatic androgen pathway modulation–naive or sensitive prostate cancer.

Revumenib yielded responses across subgroups with relapsed/refractory, NPM1-mutated AML and co-mutations, as well as in KMT2A-rearranged acute leukemia.

Azacitidine plus venetoclax and ivosidenib produced robust responses and induced high rates of MRD negativity in IDH1-mutated newly diagnosed AML.

In case you missed any, check out our recap of the episodes of OncLive On Air that aired in May 2026.

Experts highlight the most interesting and potentially paradigm-shifting head and neck cancer data to come out of the 2026 ASCO Annual Meeting.

Megan Kruse, MD, discusses CDK4/6 inhibitor decision-making for patients with HR-positive breast cancer and future directions for oral SERD and ADC use.

Read a refresh of the top FDA news in breast cancer from May 2026, including several key approvals across ER-positive and triple-negative disease.

The EU has approved the use of subcutaneous isatuximab delivered via OBI across all existing indications for IV isatuximab for multiple myeloma.

Breast cancer data from ASCO 2026 confirm the clinical benefits of several investigational treatment approaches across disease subtypes.

HER3-DXd is being evaluated in the ongoing phase 3 HERTHENA-Breast04 trial in locally advanced or metastatic HR-positive, HER2-negative breast cancer.

Post-surgery ctDNA status was prognostic for distant recurrence in early TNBC, and the prognostic value of ctDNA status per WGS outperformed pCR status.

At the 2026 ASCO Annual Meeting, 3.5-year follow-up findings from the phase 3 EV-302/KEYNOTE-A39 study have been presented.

David Dinh Tran, MD, PhD, discusses the use of LITT followed by pembrolizumab in patients with recurrent high-grade astrocytoma.

At the 2026 ASCO Annual Meeting, results from the 7-year update of the phase 3 CROWN study were presented.

Gabriel Zada, MD, discusses advanced surgical techniques for brain cancer in light of Brain Tumor Awareness Month.

The FDA extended the review period for camizestrant plus a CDK4/6 inhibitor in hormone receptor–positive breast cancer with an emergent ESR1 mutation.

A DSMB has recommended the continuation of the BRIA-ABC trial evaluating Bria-IMT in patients with metastatic breast cancer, with no safety concerns.

Bispecific antibodies and the latest proton therapy techniques are taking center stage in the treatment of patients with head and neck cancers.

Yelena Novik, MD, notes the use of CDK4/6 inhibitors in ER-positive breast cancer and the role of oral SERDs in the management of select metastatic cases.

Biomarker analyses indicate that CD47 expression may help predict benefit from zanidatamab plus evorpacept in HER2-positive metastatic breast cancer.

In case you missed any, check out our recap of the episodes of OncLive On Air that aired in April 2026.

Breast cancer experts discuss the nuances of ESR1 mutations and oral SERD use in hormone receptor–positive breast cancer.

Emi-Le received breakthrough therapy designation from the FDA for the treatment of patients with locally advanced, recurrent or metastatic ACC.

First-line INBRX-106 plus pembrolizumab generated a higher ORR vs pembrolizumab monotherapy in PD-L1–positive metastatic or unresectable HNSCC.

Sacituzumab govitecan plus trastuzumab following T-DXd did not meet the primary end point of the SATEEN trial in HER2+ metastatic breast cancer.

Capivasertib plus fulvestrant generated a numerical OS benefit vs placebo plus fulvestrant in PIK3CA/AKT1/PTEN-altered advanced breast cancer.